Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS trial of ziltivekimab versus placebo in ASCVD with chronic kidney disease and systemic inflammation
CTR20220872Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ziltivekimab in atherosclerotic disease, chronic kidney disease (CKD), chronic inflammation, sponsored by Novo Nordisk. Started May 2022; status: completed.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)chronic inflammation
Beyond the preview
Go deeper on CTR20220872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220872.